FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247320809> ?p ?o ?g. }

• W4247320809 abstract "Background Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain. Objectives To determine whether selective CB1 receptor antagonists increase the numbers of people stopping smoking To assess their effects on weight change in successful quitters and in those who try to quit but fail. Search methods We searched the Cochrane Tobacco Addiction Review Group specialized register for trials, using the terms 'rimonabant' and 'smoking' in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, CINAHL and PsycINFO, using major MESH terms. We acquired electronic or paper copies of posters of preliminary trial results presented at the American Thoracic Society Meeting in 2005, and at the Society for Research on Nicotine and Tobacco European Meeting 2006. We also attempted to contact the authors of ongoing studies of rimonabant, and Sanofi Aventis (manufacturers of rimonabant). Selection criteria Types of studies Randomized controlled trials Types of participants Adult smokers Types of interventions Selective CB1 receptor antagonists, such as rimonabant. Types of outcome measures The primary outcome is smoking status at a minimum of six months after the start of treatment. We preferred sustained cessation rates to point prevalence, and biochemically verified cessation to self‐reported quitting. We regarded smokers who drop out or are lost to follow up as continuing smokers. We have noted any adverse effects of treatment. A secondary outcome is weight change associated with the cessation attempt. Data collection and analysis Two authors checked the abstracts for relevance, and attempted to acquire full trial reports. One author extracted the data, and a second author checked them. Main results We found three trials which met our inclusion criteria, covering 1567 smokers (cessation: STRATUS‐EU and STRATUS‐US), and 1661 quitters (relapse prevention: STRATUS‐WW). At one year, the pooled risk ratio (RR) for quitting with rimonabant 20 mg was 1.50 (95% confidence interval (CI) 1.10 to 2.05). No significant benefit was demonstrated for rimonabant at 5 mg dosage. Adverse events included nausea and upper respiratory tract infections. In the relapse prevention trial, smokers who had quit on the 20 mg regimen were more likely to remain abstinent on either active regimen than on placebo; the RR for the 20 mg maintenance group was 1.29 (95% CI 1.06 to 1.57), and for the 5 mg maintenance group 1.30 (95% CI 1.06 to 1.59). There appeared to be no significant benefit of maintenance treatment for the 5 mg quitters. Weight gain was reported to be significantly lower among the 20 mg quitters than in the 5 mg or placebo quitters. During treatment, overweight or obese smokers tended to lose weight, while normal weight smokers did not. Post‐marketing surveillance has led the European Medicines Agency (EMEA) to require themanufacturers to withdraw the drug, because of links to mental disorders. Authors' conclusions From the preliminary trial reports available, rimonabant 20 mg may increase the chances of quitting approximately 1½‐fold. Adverse events include nausea and upper respiratory tract infections; the risk of serious adverse events is reported to be low. However, in October 2008 post‐marketing surveillance led to the withdrawal of rimonabant as a prescription drug in European countries, because of links to mental disorders. The evidence for rimonabant in maintaining abstinence is inconclusive. Rimonabant 20 mg may moderate weight gain in the long term." @default.
• W4247320809 created "2022-05-12" @default.
• W4247320809 creator A5008101890 @default.
• W4247320809 creator A5019012827 @default.
• W4247320809 date "2007-10-17" @default.
• W4247320809 modified "2023-09-30" @default.
• W4247320809 title "Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation" @default.
• W4247320809 cites W1508039321 @default.
• W4247320809 cites W2081403760 @default.
• W4247320809 cites W2098026971 @default.
• W4247320809 cites W2110180322 @default.
• W4247320809 cites W2115129983 @default.
• W4247320809 cites W2142215961 @default.
• W4247320809 cites W2142801463 @default.
• W4247320809 cites W2155415459 @default.
• W4247320809 doi "https://doi.org/10.1002/14651858.cd005353.pub3" @default.
• W4247320809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17943852" @default.
• W4247320809 hasPublicationYear "2007" @default.
• W4247320809 type Work @default.
• W4247320809 citedByCount "49" @default.
• W4247320809 countsByYear W42473208092012 @default.
• W4247320809 countsByYear W42473208092013 @default.
• W4247320809 countsByYear W42473208092014 @default.
• W4247320809 countsByYear W42473208092015 @default.
• W4247320809 countsByYear W42473208092017 @default.
• W4247320809 countsByYear W42473208092018 @default.
• W4247320809 countsByYear W42473208092020 @default.
• W4247320809 countsByYear W42473208092021 @default.
• W4247320809 countsByYear W42473208092023 @default.
• W4247320809 crossrefType "reference-entry" @default.
• W4247320809 hasAuthorship W4247320809A5008101890 @default.
• W4247320809 hasAuthorship W4247320809A5019012827 @default.
• W4247320809 hasConcept C118552586 @default.
• W4247320809 hasConcept C126322002 @default.
• W4247320809 hasConcept C142724271 @default.
• W4247320809 hasConcept C148001335 @default.
• W4247320809 hasConcept C168563851 @default.
• W4247320809 hasConcept C170493617 @default.
• W4247320809 hasConcept C17744445 @default.
• W4247320809 hasConcept C1862650 @default.
• W4247320809 hasConcept C199539241 @default.
• W4247320809 hasConcept C27415008 @default.
• W4247320809 hasConcept C2776433454 @default.
• W4247320809 hasConcept C2776885963 @default.
• W4247320809 hasConcept C2777843972 @default.
• W4247320809 hasConcept C2779473830 @default.
• W4247320809 hasConcept C2779547902 @default.
• W4247320809 hasConcept C2779549880 @default.
• W4247320809 hasConcept C2780478649 @default.
• W4247320809 hasConcept C2780871563 @default.
• W4247320809 hasConcept C2781145037 @default.
• W4247320809 hasConcept C71924100 @default.
• W4247320809 hasConcept C95190672 @default.
• W4247320809 hasConceptScore W4247320809C118552586 @default.
• W4247320809 hasConceptScore W4247320809C126322002 @default.
• W4247320809 hasConceptScore W4247320809C142724271 @default.
• W4247320809 hasConceptScore W4247320809C148001335 @default.
• W4247320809 hasConceptScore W4247320809C168563851 @default.
• W4247320809 hasConceptScore W4247320809C170493617 @default.
• W4247320809 hasConceptScore W4247320809C17744445 @default.
• W4247320809 hasConceptScore W4247320809C1862650 @default.
• W4247320809 hasConceptScore W4247320809C199539241 @default.
• W4247320809 hasConceptScore W4247320809C27415008 @default.
• W4247320809 hasConceptScore W4247320809C2776433454 @default.
• W4247320809 hasConceptScore W4247320809C2776885963 @default.
• W4247320809 hasConceptScore W4247320809C2777843972 @default.
• W4247320809 hasConceptScore W4247320809C2779473830 @default.
• W4247320809 hasConceptScore W4247320809C2779547902 @default.
• W4247320809 hasConceptScore W4247320809C2779549880 @default.
• W4247320809 hasConceptScore W4247320809C2780478649 @default.
• W4247320809 hasConceptScore W4247320809C2780871563 @default.
• W4247320809 hasConceptScore W4247320809C2781145037 @default.
• W4247320809 hasConceptScore W4247320809C71924100 @default.
• W4247320809 hasConceptScore W4247320809C95190672 @default.
• W4247320809 hasLocation W42473208091 @default.
• W4247320809 hasLocation W42473208092 @default.
• W4247320809 hasOpenAccess W4247320809 @default.
• W4247320809 hasPrimaryLocation W42473208091 @default.
• W4247320809 hasRelatedWork W2021292659 @default.
• W4247320809 hasRelatedWork W2048743691 @default.
• W4247320809 hasRelatedWork W2079272094 @default.
• W4247320809 hasRelatedWork W2331358065 @default.
• W4247320809 hasRelatedWork W3087684531 @default.
• W4247320809 hasRelatedWork W3092155507 @default.
• W4247320809 hasRelatedWork W4225116982 @default.
• W4247320809 hasRelatedWork W4294126851 @default.
• W4247320809 hasRelatedWork W4311201195 @default.
• W4247320809 hasRelatedWork W4318570223 @default.
• W4247320809 isParatext "false" @default.
• W4247320809 isRetracted "false" @default.
• W4247320809 workType "reference-entry" @default.